Two US senators, Democratic Senator Kirsten Gillibrand and Republican Senator Rick Scott, have put forth a bill that aims to enhance transparency in the pharmaceutical supply chain. The proposed legislation, known as the CLEAR LABELS Act, seeks to mandate the disclosure of the manufacturing origins of prescription drugs on their labels in the United States.
Gillibrand emphasized the importance of informing Americans about where their prescription medications are produced to enable them to make informed healthcare choices. She highlighted that the bill would ensure easy access to manufacturing information and enhance accountability in the pharmaceutical supply chain. Additionally, Gillibrand mentioned that the measure would facilitate access to safe and effective medications by providing clear and reliable information to patients and healthcare providers.
Scott expressed concern that families currently lack essential information regarding the sources of their medicines. He stressed the need for transparency in drug manufacturing, particularly as the US heavily relies on foreign countries like China and India for drug production. Scott pointed out that the lack of transparency and oversight poses risks to patients and emphasized the importance of ensuring the safety and clarity of drug labeling.
The CLEAR LABELS Act, if passed, would require prescription drug labels to disclose the original manufacturers of both finished drugs and active pharmaceutical ingredients (APIs). This information could be directly printed on the label or made accessible through electronic means like links, barcodes, or QR codes linked to a searchable database. The senators believe that this initiative would provide patients and regulators with upfront information on drug origins, aiding in identifying vulnerabilities in the drug supply chain and safeguarding the availability of safe treatments.
The proposed legislation builds upon previous bipartisan efforts by Gillibrand and Scott, which involved investigations and inquiries into the US reliance on foreign-made generic drugs. By amending the Federal Food, Drug, and Cosmetic Act, the bill aims to expand labeling requirements and enhance transparency throughout the prescription drug supply chain.
